drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (genetically modified autologous T cells)
drug_description
Autologous, gene-modified T lymphocytes engineered with a CD70-specific chimeric antigen receptor; a single IV infusion that targets CD70-positive tumor cells to trigger T-cell activation and cytotoxicity.
nci_thesaurus_concept_id
C201176
nci_thesaurus_definition
Any preparation of chimeric antigen receptor (CAR) expressing T-lymphocytes that targets the tumor-associated antigen (TAA) CD70.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a CD70-specific chimeric antigen receptor; upon binding CD70 on tumor cells, the CAR triggers T-cell activation and expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD70-positive cells.
drug_name
Anti-CD70 CAR-T cells
nct_id_drug_ref
NCT06586658